Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377207 | 0.89 | TSHR (0.38) | GAATSHRMAPTMAPK1HTT | |
| SCHEMBL10685629 | 0.87 | GAA (0.36) | GAATSHRMAPTMAPK1HTT | |
| SCHEMBL6426022 | 0.82 | GAA (0.48) | GAATSHRMAPTMAPK1HTT | |
| SCHEMBL249358 | 0.80 | ALDH1A1 (0.43) | GAATSHRMAPTMAPK1HTT | |
| SCHEMBL5388127 | 0.80 | TSHR (0.41) | GAATSHRMAPTMAPK1HTT | |
| SCHEMBL5382824 | 0.78 | RORC (0.58) | GAATSHRMAPK1HTTALDH1A1 | |
| SCHEMBL12444685 | 0.78 | ALDH1A1 (0.46) | GAATSHRMAPTALDH1A1USP2 | |
| SCHEMBL5050253 | 0.78 | ALDH1A1 (0.46) | GAATSHRALDH1A1USP2PKM | |
| SCHEMBL1772000 | 0.76 | GAA (0.43) | GAATSHRMAPTHTTALDH1A1 | |
| SCHEMBL10882492 | 0.74 | ALDH1A1 (0.46) | GAATSHRMAPTALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013009372-A1 | PHOSPHORUS-CONTAINING SECONDARY AMINE COMPOUNDS | HUNTSMAN PETROCHEMICAL LLC (US) | 2013-01-17 | — | — | WO | disclosed |
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8143365-B2 | Formulations for reaction injection molding and for spray systems | ALBEMARLE CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8080626-B2 | Chain extenders | ALBEMARLE CORPORATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-7964695-B2 | Chain extenders | ALBEMARLE CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110137005-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010101560-A1 | BIS[(ALKYLAMINO)ALKYL]AMINES | ALBEMARLE CORPORATION (US) | 2010-09-10 | — | — | WO | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2102265-A1 | FORMULATIONS FOR REACTION INJECTION MOLDING AND FOR SPRAY SYSTEMS | Albermarle Corporation (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080194788-A1 | Diimines and Secondary Diamines | ALBEMARLE CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008086437-A1 | FORMULATIONS FOR REACTION INJECTION MOLDING AND FOR SPRAY SYSTEMS | ALBEMARLE CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008039571-A1 | DIAMINE CHAIN EXTENDER COMPOSITIONS | ALBEMARLE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070270566-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | GAA 4833/4885TSHR 3124/4885MAPT 1803/4885 |
| US-20070270566-A1 | Chain Extenders | DDC, PARG, ODC1 | GAA 3496/4885TSHR 4124/4885MAPT 1760/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | GAA 4833/4885TSHR 3124/4885MAPT 1803/4885 |
| US-20080194788-A1 | Diimines and Secondary Diamines | DDT, DDC, AOC1 | GAA 4865/4885TSHR 2793/4885MAPT 2583/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | GAA 4833/4885TSHR 3124/4885MAPT 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.